What are IL-5 receptor antagonist monoclonal antibody drugs?

IL-5 receptor antagonist monoclonal antibody drugs are pharmacologic agents that share a common mechanism (typically targeting IL-5 receptor alpha (IL-5Rα)). 3 are currently marketed, with 4 more in clinical development.

What are the marketed IL-5 receptor antagonist monoclonal antibody drugs?

Marketed IL-5 receptor antagonist monoclonal antibody drugs include Benralizumab Prefilled Syringe, anti IL5 receptor antibodies, Fasenra®.

IL-5 receptor antagonist monoclonal antibody

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3 marketed 4 in Phase 3

This page covers all IL-5 receptor antagonist monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-5 receptor alpha (IL-5Rα), IL-5 receptor (IL-5R), IL-5Rα (interleukin-5 receptor alpha).

Targets

IL-5 receptor alpha (IL-5Rα) · IL-5 receptor (IL-5R) · IL-5Rα (interleukin-5 receptor alpha) · IL-5RA (Interleukin-5 Receptor Alpha) · IL-5 receptor alpha (CD125)

Marketed (3)

Benralizumab Prefilled Syringe · Nantes University Hospital · Immunology / Respiratory
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.
anti IL5 receptor antibodies · Scarlata, Simone, M.D. · Immunology
Anti-IL-5 receptor antibodies block the interleukin-5 receptor on eosinophils, preventing eosinophil activation and reducing eosinophilic inflammation.
Fasenra® · AstraZeneca · Immunology / Respiratory
Fasenra is a monoclonal antibody that binds to and depletes interleukin-5 receptor alpha (IL-5Rα) on eosinophils, reducing eosinophil levels in the blood and tissues.

Phase 3 pipeline (4)

Benralizumab Arm C · AstraZeneca · Immunology / Respiratory
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.
Benralizumab Arm B · AstraZeneca · Immunology / Respiratory
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduced airway inflammation.
Benralizumab Arm A · AstraZeneca · Immunology
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.
Benralizumab (Medi-563) · AstraZeneca · Immunology / Respiratory
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.

Patent intelligence

il 5 receptor antagonist monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates